Vibrato Medical Raises Funds, Receives NIH Grant to Support its Wearable Device to Treat CLI

September 14, 2021—Vibrato Medical, an Irvine, California–based company focused on the treatment of peripheral artery disease (PAD), announced that it has closed a $4 million Series A funding round, led by the Horowitz Group, a multiasset class family investment office based in Newport Beach, California. Additionally, the company received a $1.5 million grant from the National Institutes of Health.

According to the company, the combined funding will support the clinical trial of the company’s noninvasive wearable device designed to treat patients with critical limb ischemia (CLI) from their homes. Using therapeutic ultrasound, the device is designed to promote vasodilation, collateral vessel growth, and angiogenesis and restore perfusion. It is appropriate for daily treatments. With the funds, the company plans to conduct a pilot clinical study for the device to design and build its second-generation device and advance its intellectual property.

Vibrato was founded by cardiologist and physician-scientist Babak Nazer, MD, and entrepreneur Bobak Azamian, MD, PhD.

Juliana Elstad, who serves as Chief Executive Officer of Vibrato, commented in the announcement, “Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI. Our recent funding puts us on the path toward that vision. We’re excited for the day when our device allows these patients to take control of their health and lower extremity perfusion to live the lives they deserve.”

Jason Tester, Chief Financial Officer at Horowitz Group, added, “CLI is a highly undertreated condition with dire consequences for patients. We are excited to partner with Vibrato Medical on the development of a truly novel technology to treat this terrible condition.”